Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

ommercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by The University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Re
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biologics ... their offering. , The Global ... professional and in-depth study on the current state ... The report provides a basic overview of the ...
(Date:3/4/2015)... March 04, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... to Optimize the Management of Pain”. , The ... Medscape.com for the next year. The focus of ... to recognize inadequate pain treatments, integrate appropriate pain ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... Hopitaux de Paris en ... «   SARAH   », qui compare   ... l,yttrium-90 avec le   sorafénib dans le carcinome ... atteints d,un cancer du foie avancé   ; ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... BALTIMORE, Sept. 13 Champions Biotechnology, Inc. (OTC Bulletin Board: ... of advanced preclinical platforms and tumor specific data to enhance ... for the fiscal 2011 first quarter ended July 31, 2010. ... in the Company,s Form 10-Q at www.championsbiotechnology.com . ...
... Berkeley Engineers at the University of California, Berkeley, ... that could one day give new meaning to the ... a material that functions like the human skin, which ... said Ali Javey, associate professor of electrical engineering and ...
... Corporation Reports First Quarter Fiscal 2011 Financial Results. Revenue Increases 23.8% to RMB71.7 ... ET September 10, 2010." /> China Cord Blood Corporation Reports First ... ... ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 11China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results 12
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Speedy diagnosis of the temper and vital signs of ... humanity, says a distinguished partnership of international scientists urging ... 10 years. The Partnership for Observation of the ... are among profound concerns that must be better measured ...
... found that the children of mothers whose water supplies ... expression changes that may lead to cancer and other ... potential harmful effects of these prenatal exposures, the new ... to detect signs of arsenic contamination. This is ...
... Company Anticipates Acquisition Could More Than Double its Current ... the Medical and Healthcare Industry, SAN JOSE, Calif., ... a leading biometric and security,solutions provider, announced today the ... Medical Systems (OTC: CHSY), a company listed in,the US ...
Cached Biology News:Human safety, prosperity depend on better ocean observing system: Scientists 2Human safety, prosperity depend on better ocean observing system: Scientists 3Human safety, prosperity depend on better ocean observing system: Scientists 4Human safety, prosperity depend on better ocean observing system: Scientists 5Human safety, prosperity depend on better ocean observing system: Scientists 6Human safety, prosperity depend on better ocean observing system: Scientists 7Human safety, prosperity depend on better ocean observing system: Scientists 8MIT: Prenatal arsenic exposure detected in newborns 2MIT: Prenatal arsenic exposure detected in newborns 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4